Clinical Trial Detail

NCT ID NCT02607553
Title Safety and Activity of G-202 in Patients With Clear Cell Renal Cell Carcinoma That Expresses PSMA
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors GenSpera, Inc.
Indications

clear cell renal cell carcinoma

Therapies

Mipsagargin

Age Groups: senior adult

No variant requirements are available.